- miR-195/miR-497 Regulate CD274 Expression of Immune Regulatory Ligands in Triple-Negative Breast Cancer
-
Yang L, Cai Y, Zhang D, Sun J, Xu C, Zhao W, Jiang W, Pan C
- KMID: 2429815
- J Breast Cancer.
- 2018 Dec;21(4):371-381.
- doi: 10.4048/jbc.2018.21.e60
PURPOSE: Immune suppression is common in patients with advanced breast cancer but the mechanisms underlying this phenomenon have not been sufficiently studied. In this study, we aimed to identify B7... -
- CITED
-
- Close
- SHARE
-
- Close
- Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy
-
Kim KH, Kim CG, Shin EC
- KMID: 2471048
- Immune Netw.
- 2020 Feb;20(1):e8.
- doi: 10.4110/in.2020.20.e8
Immune checkpoint blockade targeting PD-1 and PD-L1 has resulted in unprecedented clinical benefit for cancer patients. Anti-PD-1/PD-L1 therapy has become the standard treatment for diverse cancer types as monotherapy or... -
- CITED
-
- Close
- SHARE
-
- Close
- Early Experiences with Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Failed Target Therapy
-
Lee JH, Kang M, Chung JH, Sung HH, Jeon HG, Jeong BC, Jeon SS, Lee HM, Park SH, Kim B, Kwon GY, Seo SI
- KMID: 2457593
- Korean J Urol Oncol.
- 2019 Aug;17(2):96-102.
- doi: 10.22465/kjuo.2019.17.2.96
PURPOSE: The efficacy of nivolumab in metastatic renal cell carcinoma (mRCC) has been proven. However, the nivolumab experience in Korean patients with mRCC is still poorly reported. We report initial... -
- CITED
-
- Close
- SHARE
-
- Close
- Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
-
Kim SJ, Kim S, Kim DW, Kim M, Keam B, Kim TM, Lee Y, Koh J, Jeon YK, Heo DS
- KMID: 2454314
- Cancer Res Treat.
- 2019 Jul;51(3):1231-1240.
- doi: 10.4143/crt.2018.486
PURPOSE: The purpose of this study was to evaluate the relationships between the resistance of anaplastic lymphoma kinase (ALK)‒positive non-small cell lung cancer (NSCLC) to ALK inhibitors and the programmed... -
- CITED
-
- Close
- SHARE
-
- Close
- Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma
-
Iijima M, Okonogi N, Nakajima N, Morokoshi , Kanda H, Yamada T, Kobayashi , Banno K, Wakatsuki , Yamada S, Kamada T, Aoki D, Hasegawa S
- KMID: 2470870
- J Gynecol Oncol.
- 2020 Mar;31(2):e19.
- doi: 10.3802/jgo.2020.31.e19
OBJECTIVE: Programmed cell death-ligand 1 (PD-L1) is expressed in tumor cells and has been shown to predict clinical outcomes of several types of malignancies. The aim of this study was... -
- CITED
-
- Close
- SHARE
-
- Close
